|
|
News Breaks | | | | October 8, 2012 | | 12:00 EDT |  | GRFS | Grifols: First patient enrolled in Phase 2 trial of Alpha-1 HC
Grifols announced that the first patient has been enrolled and dosed in a phase II study evaluating the safety and tolerability of Alpha-1 HC aerosol in patients with cystic fibrosis. Cystic fibrosis is an inherited disease that causes progressive decline in lung function, including acute episodes of worsening respiratory symptoms and potentially fatal lung infections. The multicenter trial will investigate two doses of Alpha-1 HC aerosol, an inhaled formulation of Grifols' alpha1-proteinase inhibitor (human). Investigators will measure adverse events and other end points during the three-week study period. The randomized, double-blind, placebo-controlled trial will enroll 30 patients at six sites across the U.S. | |
|
News For GRFS From The Last 14 Days Check below for free stories on GRFS the last two weeks. |
|
|
| May 22, 2013 | | 08:49 EDT | | GRFS | Grifols presents positive results from study of Prolastin
 Subscribe for More Information | |
|
|
|
|
|
|
